On August 4, 2016, in the conference hall of Beijing Haoyuan Jianguo Hotel, the "Seventh Northern Region Lymphatic Treatment Center" was jointly organized by the "Peking University Hematology Lymphatic Treatment Center" and the "Clinical Oncology Professional Committee of the C...

Recently, Shenzhen Yishi Kangning Biotechnology Co., Ltd. has obtained the enterprise credit rating "AAA" certificate issued by Beijing Guofutai Credit Management Co., Ltd., a credit service agency in the business field recommended by the State-owned Assets Supervision and Admini...

In March of Yangchun, everything recovers, and the land of Jiangsu is full of vitality. On March 13, more than 200 experts from all over Jiangsu Province gathered together to participate in the multi-center clinical research kick-off meeting of ACTL targeted anti-tumor cell immune techno...

Recently, the Jiangsu Provincial Health and Family Planning Commission and other relevant units decided to hold the signing ceremony of the multi-center clinical trial of ACTL targeted anti-tumor cell immune technology in Nanjing, Jiangsu Province on March 13, 2016. ACTL technolog...

After more than a year of exchanges and preparations, ACTL targeted anti-tumor cell immune technology finally settled in Hefei, Anhui Province, and patients in and around Anhui Province can receive this advanced anti-tumor treatment nearby. Recently, the Hefei Tumor Hospital of the Ch...